Every Form 4 that Nuvalent, Inc. (NUVL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NUVL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVL filings page.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported a mix of stock sales and new equity awards. On January 5–6, 2026, he sold multiple blocks of Nuvalent Class A Common Stock in open-market transactions, including 513 shares at a weighted average price of $96.06, 660 shares at $96.85, 1,137 shares at $97.96, 186 shares at $98.52, 1,106 shares at $96.75, 1,369 shares at $97.33 and 189 shares at $98.40.
According to the footnotes, these sales were made under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations on vesting equity awards. On January 7, 2026, Pelish acquired 17,500 shares of Class A Common Stock for $0.00 pursuant to restricted stock units that vest in three equal annual installments after January 7, 2026, and received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported several sales and equity awards involving the company’s Class A Common Stock. On January 5 and 6, 2026, she sold multiple small blocks of shares under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations upon vesting of earlier equity awards. Reported weighted average sale prices include $96.06, $96.85, $97.96 and $98.52 per share.
On January 7, 2026, Noci reported an acquisition of 17,500 Class A shares for $0.00 per share, representing restricted stock units that vest in three equal annual installments following that date, subject to continued service. She also received a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026. Following these transactions, she directly owned 58,117 Class A shares and 17,500 stock options.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported multiple transactions in the company’s Class A Common Stock. On January 5–6, 2026, she sold several small blocks of shares at weighted average prices generally ranging from about $95.34 to $99.10 per share, with the filing noting these sales were made under a durable Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding obligations on previously granted equity awards.
On January 7, 2026, she received 17,500 restricted stock units (RSUs), each representing one share of Class A Common Stock, which vest in three equal annual installments following that date, and a stock option for 17,500 shares at an exercise price of $106.82 that vests in equal monthly installments over four years. After these transactions, she directly beneficially owned 59,634 shares of Class A Common Stock and 17,500 stock options.
Nuvalent, Inc. Chief Medical Officer Christopher Durant Turner reported multiple sales of Class A common stock on January 5–6, 2026, at weighted average prices generally in the $96–$99 range. The filing notes these sales were executed under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to cover tax withholding on previously vested equity awards.
On January 7, 2026, he reported the acquisition of 17,500 restricted stock units (RSUs), each representing one share of Class A common stock, which vest in three equal annual installments following January 7, 2026, subject to continued service. He also received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years following January 7, 2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported several transactions in the company’s Class A common stock. On January 5 and 6, 2026, she sold small blocks of shares at weighted average prices ranging from about $95 to $99 per share under a durable Rule 10b5-1 sell-to-cover instruction, used to satisfy tax withholding on previously granted equity awards. After these sales, she continued to hold tens of thousands of shares directly.
On January 7, 2026, Balcom received 17,500 restricted stock units, each representing one share of Nuvalent Class A common stock. These RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. She was also granted a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years following January 7, 2026, also conditioned on continued service.
Nuvalent, Inc. President and CEO James Richard Porter reported multiple stock transactions in early January 2026. On January 5–6, 2026, he sold several blocks of Nuvalent Class A Common Stock under a pre-arranged Rule 10b5-1 sell-to-cover instruction, with weighted average prices ranging from about $96 to $99 per share to cover tax withholding on previously vested equity awards. After these sales, his directly held shares were reduced to 278,629.
On January 7, 2026, Porter received 46,250 restricted stock units (RSUs) for Class A Common Stock at a stated price of $0.00, increasing his directly held shares to 324,879. The RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. He was also granted a stock option for 46,250 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026.
Nuvalent, Inc. reported that one of its directors acquired equity on December 10, 2025. The director received 2,837 shares of Class A common stock issuable under restricted stock units at a price of $0.00, bringing direct ownership of Class A common stock to 2,837 shares.
The director also acquired a stock option for 4,418 shares of Class A common stock with an exercise price of $105.74 and an expiration date of December 10, 2035. The RSUs vest in three equal annual installments after December 10, 2025, while the stock option vests over the three years following that date in equal monthly installments, in each case subject to continued service.
Nuvalent, Inc. (NUVL) reported insider stock sales by a director on 11/24/2025. The reporting person sold multiple small blocks of Class A common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2024.
The Form 4 shows sales at weighted average prices ranging from about $107.01 to $110.64 per share, including transactions reported at weighted averages of $107.70, $108.73, $109.77 and $110.42. After these transactions, the reporting person beneficially owned 1,378,387 Class A common shares directly and 201,672 shares indirectly through the Matthew D. Shair 2021 Irrevocable Family Trust, over which the reporting person has voting and dispositive power.
Nuvalent, Inc. (NUVL) reported an insider transaction by a group of affiliated investment funds and entities that are directors, 10% owners, and directors by deputization. On 11/24/2025, Deerfield Private Design Fund IV, L.P. and Deerfield Healthcare Innovations Fund, L.P. each reported selling 371,287 shares of Nuvalent Class A common stock pursuant to the exercise of underwriters' option to cover over-allotments in an underwritten public offering at a price of $95.445 per share, while the shares were sold to the public at $101.00 per share. Following the reported transactions, the filing shows 8,299,225 shares of Class A common stock beneficially owned indirectly through Deerfield Private Design Fund IV, L.P. and Deerfield Healthcare Innovations Fund, L.P., and 650,000 shares indirectly through Deerfield Partners, L.P. The reporting persons state they disclaim beneficial ownership beyond their indirect pecuniary interest.
Nuvalent, Inc. (NUVL) filed a Form 4 for its Chief Financial Officer detailing option exercises and stock sales in November 2025. On November 17, 2025, the CFO exercised stock options for 6,875 Class A shares at $6.89 and 13,125 shares at $72.35, then sold multiple blocks of Class A Common Stock at weighted average prices ranging from $93.8 to $103.68. On November 18, 2025, additional options for 729 shares at $72.35 were exercised, with share sales at weighted average prices of $103.61 and $104.54. After these transactions, the CFO directly owned 61,734 Class A shares and held stock options covering 29,101 and 33,646 shares. All reported trades were made under a Rule 10b5-1 trading plan adopted on December 12, 2024.
Nuvalent, Inc. (NUVL) reported insider activity by its Chief Legal Officer on a Form 4. On 11/17/2025, the officer exercised a stock option for 24,200 shares of Class A common stock at an exercise price of $6.89 per share. That same day, the officer sold 15,075 shares at a weighted average price of $105.16, 8,517 shares at $105.98, and 608 shares at $107.04, all under a Rule 10b5-1 trading plan adopted on November 18, 2024. After these transactions, the officer directly owned 49,086 shares of Class A common stock and held 94,608 stock options that remain beneficially owned, with the option covering 24,200 shares fully vested and expiring on 04/29/2031.
Nuvalent, Inc. (NUVL) reported an insider transaction by its Chief Development Officer on 10/30/2025. The officer exercised 4,000 stock options at $27.85 and, the same day, sold 4,000 Class A shares across multiple trades, executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
The reported sales were in tranches including 57 shares at $98.91 (weighted average, range $98.16–$99.13) and additional lots at weighted average prices of $100.69, $102.07, $103.09, $104.21, and a final sale at $104.58. Following these transactions, the officer directly held 48,034 Class A shares. Derivative holdings reported after the exercise were 122,329 stock options outstanding, with the option series expiring on 01/06/2033 and vesting monthly over four years from January 6, 2023.
Nuvalent (NUVL) reported insider activity by its Chief Legal Officer on 10/30/2025. The officer exercised 21,800 stock options at an exercise price of $6.89 and sold an equal 21,800 Class A shares in multiple same‑day open‑market transactions with weighted average prices disclosed for each tranche.
Tranche prices reported include weighted averages of $96.65, $97.98, $99.66, $100.96, $102.00, $102.88, $103.90, and $104.78. Following the transactions, the officer directly owned 49,086 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted on November 18, 2024, and the option exercised was fully vested; 118,808 derivative securities were beneficially owned after the transactions.
Nuvalent (NUVL) director Matthew D. Shair reported open-market sales of Class A common stock executed under a Rule 10b5-1 trading plan adopted on November 20, 2024.
On 10/27/2025, he sold 14,345 shares at a weighted average price of $100.23 and 4,046 shares held indirectly by the Matthew D. Shair 2021 Irrevocable Family Trust at a weighted average price of $100.23. On 10/28/2025, he sold 32,455 shares at a weighted average price of $100.27 and 9,154 indirect shares at a weighted average price of $100.27. Following these transactions, he beneficially owned 1,383,044 shares directly and 203,322 shares indirectly.
Nuvalent, Inc. (NUVL) reported an insider transaction by its Chief Legal Officer. On 10/20/2025, the officer exercised 5,000 stock options at an exercise price of $6.89 per share and sold 5,000 Class A shares at a weighted average price of $94.91 (range $94.80–$95.00). These trades were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
Following the transactions, the reporting person directly beneficially owned 49,086 Class A shares and held 140,608 derivative securities (stock options) with an option expiration date of 04/29/2031. The filing notes the underlying option shares are fully vested.
Nuvalent (NUVL): CEO insider transaction — On 10/16/2025, the President and CEO (also a Director) exercised 27,000 stock options at $18.93 per share and sold an aggregate 27,000 Class A shares in multiple tranches pursuant to a Rule 10b5-1 trading plan.
Weighted-average sale prices by tranche were $90.01 for 11,310 shares, $90.91 for 13,876 shares, $92.19 for 1,114 shares, and $92.63 for 700 shares. Following these transactions, the reporting person beneficially owned 249,062 Class A shares directly. Derivative holdings reported include 222,400 stock options remaining after the exercise.
Nuvalent, Inc. (NUVL): The Chief Legal Officer reported option exercises and open-market sales under a Rule 10b5-1 plan. On 10/15/2025, 15,624 Class A shares were acquired via option exercise at $6.89 and 15,624 shares were sold at a weighted average price of $89.98. On 10/16/2025, 12,376 shares were acquired via option exercise at $6.89, followed by sales of 2,277 shares at a weighted average price of $90.54, 5,199 shares at $91.37, and 4,900 shares at $92.5.
Following these transactions, the reporting person directly owned 49,086 Class A shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. After the exercises, stock options (right to buy) remaining were 145,608 at a $6.89 exercise price, fully vested, expiring on 04/29/2031.
Nuvalent (NUVL) reported insider activity by its Chief Scientific Officer. On 10/15/2025, the officer exercised stock options for 3,668 shares at $18.93, 7,495 shares at $27.85, and 3,042 shares at $72.35, then sold 14,205 Class A shares at a weighted average price of $90.04 (range $89.84–$90.23).
The transactions were made under a Rule 10b5-1 trading plan adopted on November 1, 2024. Following these trades, the officer directly beneficially owned 65,963 Class A shares.
Nuvalent (NUVL) reported an insider transaction by its Chief Financial Officer. On 10/15/2025, the CFO exercised 1,683 stock options at $18.93 per share and sold 1,683 Class A shares at a weighted average price of $85.57, with individual sales ranging from $85.00 to $85.69. The trades were made under a Rule 10b5-1 plan adopted on December 12, 2024.
Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 28,979 derivative securities (stock options). The filing lists transaction codes M (option exercise) and S (sale).
Nuvalent (NUVL) reported insider transactions by its Chief Financial Officer. On 10/13/2025 and 10/14/2025, the CFO exercised employee stock options and sold shares pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
On 10/13, options for 6,875 shares at $6.89 and 13,125 shares at $18.93 were exercised, followed by sales totaling 20,000 shares at weighted-average prices within disclosed ranges of $87.15–$89.28. On 10/14, 20,000 options at $18.93 were exercised and 20,000 shares were sold at weighted-average prices within $85.17–$89.12. Following these transactions, the CFO beneficially owned 61,734 Class A shares directly and 30,662 options remained outstanding.
Nuvalent (NUVL) insider activity: The Chief Scientific Officer reported option exercises and open‑market sales on 10/13/2025 and 10/14/2025 under a Rule 10b5-1 trading plan adopted on November 1, 2024.
Exercises included Class A Common Stock options for 1,669 at $18.93, 4,168 at $27.85, and 1,800 at $72.35 on 10/13, and 731 at $18.93, 877 at $27.85, and 825 at $29.33 on 10/14. Sales included 7,637 at a weighted average price of $89.81 on 10/13 (range $89.80–$89.83), and on 10/14: 1,167 at $84.98 (range $84.64–$85.63), 866 at $86.11 (range $85.89–$86.81), and 400 at $87.39 (range $87.33–$87.56).
Following the reported transactions, the reporting person beneficially owned 65,963 Class A Common Stock shares directly.
Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 trading plan adopted on 12/12/2024. The filing shows purchases (option exercises) totaling 20,000 shares acquired at exercise prices of $6.89 and $18.93, and open stock option holdings of 20,000 underlying shares exercisable through 2031 and 2032. Balcom sold 20,000 Class A shares in two weighted-average-price blocks: 19,030 shares at an average of $85.43 and 970 shares at an average of $86.37, leaving 61,734 Class A shares beneficially owned after the transactions. The filing was signed by an attorney-in-fact on 10/03/2025.
Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported option exercises and sales on September 29-30, 2025. She acquired 7,588 shares on 09/29/2025 and 20,000 shares on 09/30/2025 by exercising stock options with an exercise price of $6.89 per share. Those exercises increased the number of shares underlying her options as reported in Table II to 79,638 and then to 59,638 following the reported activity.
Concurrently, Balcom sold the same numbers of Class A common shares: 7,588 shares on 09/29/2025 at a weighted average price of $85.01 (sales ranged $85.00–$85.05) and 20,000 shares on 09/30/2025 at a weighted average price reported at $85.06 (sales ranged $85.00–$85.37). After these transactions, the Form 4 shows 61,734 shares of Class A common stock beneficially owned.
Nuvalent insider transactions on 09/29/2025: Darlene Noci, Chief Development Officer, executed transactions under a Rule 10b5-1 plan adopted on November 18, 2024. She exercised a stock option to acquire 4,000 shares at an exercise price of $27.85 and contemporaneously sold 4,000 Class A common shares in multiple block sales at weighted average prices ranging from $81.39 to $84.92 across several lots.
Following these transactions the Form 4 reports 48,034 shares of Class A common stock beneficially owned and 4,000 shares subject to the option exercised, with the filing also showing 126,329 derivative securities beneficially owned following the reported transactions. The reporting attorney-in-fact signed the form on 10/01/2025.
Nuvalent, Inc. (NUVL) insider Form 4: James R. Porter, President and CEO and a director, reported transactions on 09/15/2025 effected under a Rule 10b5-1 trading plan. He acquired a stock option for 27,000 shares at an exercise price of $18.93 and simultaneously sold 27,000 shares in three tranches: 8,823 shares at a weighted average price of $78.42, 16,080 shares at $79.30, and 2,097 shares at $80.12. After these transactions the reporting person beneficially owned 249,062 shares of Class A common stock and held options covering 27,000 shares (report shows 249,400 derivative securities beneficially owned following the transactions). The filing was signed by attorney-in-fact Nathan McConarty on 09/17/2025.